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Purpose: This study explored opinions and attitudes of genetic counselors regarding
three controversial applications of preimplantation genetic diagnosis (PGD): PGD for
early-onset Alzheimer, use of embryos that are BRCA positive after PGD revealed no
disease-free embryos to be available, and PGD to select against a variant of unknown
significance (VUS) for Marfan syndrome. Methods: Genetic counselors were contacted
through the National Society of Genetic Counselors (NSGC) electronic mailing list.
Inclusion criteria required that a participant was currently practicing as a genetic
counselor, was a member of the NSGC, and has counseled patients about PGD. Twentynine participants volunteered to participate and 24 recorded interviews were transcribed
for data analysis. The survey consisted of 34 questions including demographic questions,
qualitative questions about each of the three case scenarios, and general questions about
PGD. Qualitative analysis was performed using a conventional content analysis approach
as described by Hsieh (2005). Results: Themes common to all three scenarios included:
necessity of appropriate/thorough counseling, the importance of the genetic indications,
patient perceptions, and respect for patient autonomy in decision making. Multiple
themes were also described for each unique case scenario. The majority (65%,15/23) of
participants felt PGD for an adult-onset disorder was least controversial, and PGD for a
VUS was most controversial. Conclusion: Participants felt that PGD was appropriate for
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life limiting conditions, cases where there was an established diagnosis with a known
pathogenic mutation, and when symptom severity and disease burden were significant.
Participants agreed that appropriate/thorough counseling was necessary, patient
perceptions of ‘serious’ disease were critical, and patient autonomy were key factors
when dealing with controversial applications of PGD. Ultimately, genetic counseling is
recommended and patients need to understand the benefits, disadvantages, and the
potential outcomes of PGD in order to make the decision that is most appropriate for their
families.
Keywords: Preimplantation genetic diagnosis (PGD), controversial, genetic
counselors’ opinions.
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Chapter 1. Background
First used in the 1990s to successfully prevent X-linked disease, preimplantation genetic
diagnosis (PGD) is a technique designed to prevent genetic disorders from being
inherited by future generations. Individuals who carry a known genetic mutation or
chromosome rearrangement can use PGD to identify embryos at risk of inheriting a
genetic condition. For couples at increased risk of having affected offspring, PGD is an
alternative to prenatal diagnosis, via amniocentesis or chorionic villus sampling (CVS),
in which selective termination is often used to avoid affected offspring (Chang et al.,
2011).
Since the 1990s, significant improvements have been made in the biopsy and
molecular diagnosis techniques used for PGD, which have allowed for an increasing
number of genetic disorders to be tested. Indications for PGD include aneuploidy
screening, structural chromosome rearrangements, hereditary diseases, human leukocyte
antigen typing, and maternal-fetal blood incompatibility (Chang et al., 2011). Disorders
include, but are not limited to, Huntington's disease, Marfan syndrome, hereditary cancer
syndromes, cystic fibrosis, and hundreds more (Brezina, Brezina, & Kearns, 2012).
For couples at risk for a genetic condition, there are several reproductive options.
Couples could choose to remain child free or adopt in lieu of having a biological child.
For those that decide to pursue a pregnancy, there are several options available to prevent
the birth of an affected child. One of these options is the use of donated gametes. For
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example, intrauterine insemination or in vitro fertilization (IVF) using an unaffected
sperm donor could be used in the case of X-linked or autosomal recessive conditions to
greatly reduce the risk. The use of donated oocytes from a healthy female can be used in
conjunction with IVF to prevent autosomal recessive, X-linked, and mitochondrial
conditions (Vergeer, Van Balen, & Ketting, 1998). Other couples may choose to proceed
with a natural pregnancy and may or may not use prenatal diagnosis by amniocentesis or
CVS (Vergeer et al., 1998; Harper and Sengupta, 2012).
Amniocentesis is typically performed between 15 and 20 weeks gestation and
results are received seven to 14 days later. Since the timing of an amniocentesis only
allows for second trimester termination, CVS is an alternative diagnostic procedure that
can be done between approximately 10 and 12 weeks gestation and enables the option of
first-trimester termination (Goldberg, Martin, Lebo, & Pedersen, 1993).
Preimplantation genetic diagnosis is a reproductive option that allows couples, in
many cases, to avoid pregnancy termination. Because the PGD technique requires a
priori knowledge of the genetic condition, couples who choose PGD typically have had a
previous diagnosis of a specific disorder, either in an affected child or in one of the
members of the couple. Alternatively, some couples may not have any history of a
disorder but may be aware of a positive carrier status through routine genetic carrier
screening. However, PGD is not a simple process. In addition to undergoing the physical
and emotional challenges of IVF, couples often need to have unique, specific molecular
tests designed and validated to carry-out the genetic testing (Coutelle et al., 1989).
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1.1 Preimplantation Genetic Diagnosis (PGD) and In Vitro Fertilization (IVF)
Preimplantation genetic diagnosis is performed in conjunction with IVF.
Approximately four to six percent of IVF cycles in the United States utilize PGD and
nearly 74% of fertility clinics offer PGD (Baruch, Kaufman, & Hudson, 2008). For IVF,
ovaries are stimulated using a combination of injectable hormones to produce a higher
than usual number of mature follicles. Under ultrasound guidance, oocytes are retrieved
from the ovaries by follicular fluid aspiration and fertilized in the laboratory to create
embryos (Coutelle et al., 1989). The oocytes and embryos can be tested at various stages
of development by biopsying cells through various micromanipulation procedures
(Goldberg et al., 1993).
Preimplantation genetic diagnosis involves the biopsy of polar bodies,
blastomeres, or trophectoderm from developing oocytes and embryos. Polar body biopsy
is useful for screening oocytes for maternal genetic abnormalities only, since no paternal
genetic contribution is present. In Germany and Italy, with strict regulations on embryo
biopsy, polar body biopsy is preferred because it occurs before fertilization is complete
(Brezina et al., 2012). After fertilization, the resulting embryo goes through several
stages of development. Three days after the fertilization procedure, embryos reach the
cleavage stage of development, and are approximately four to eight cells in size.
Cleavage stage biopsy involves removing one or two cells called blastomeres, and was
the most common biopsy method used in PGD for many years (Brezina et al., 2012).
Five days after the fertilization procedure, the embryo has reached the blastocyst stage
and is composed of two cell types: the inner cell mass and the trophectoderm. The inner
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cell mass is a collection of cells that eventually becomes the fetus. Trophectoderm cells
are fated to become the placenta. Biopsy at the blastocyst stage consists of removing
several trophectoderm cells. Several studies suggest more accurate PGD results with this
type of biopsy as opposed to cleavage stage biopsy (Brezina et al., 2012).
Genetic abnormalities are identified by a variety of methods such as: polymerase
chain reaction (PCR), microarrays and fluorescence in situ hybridization (FISH) (Practice
Committee of the American Society for Reproductive Medicine, 2004; Brezina et al.,
2012). Embryos that are unaffected can then be transferred to the woman’s uterus five or
six days after egg retrieval, or are cryopreserved for future use (Practice Committee of
the American Society for Reproductive Medicine, 2004). The goal of PGD is to only
transfer embryos that are most likely to be unaffected by a genetic condition (Ehrich &
Williams, 2010).
Although PGD reduces risk, it is not considered an alternative to prenatal genetic
diagnosis. Prenatal genetic diagnosis, through CVS or amniocentesis, is recommended to
confirm the PGD results, given the limitations resulting from testing the minute amount
of DNA from an embryonic cell (Practice Committee of the American Society for
Reproductive Medicine, 2004). However, PGD is an attractive means of excluding
embryos with genetic abnormalities and its use is becoming increasingly common.
1.2 Benefits and Limitations
The benefits of this technology include the avoidance of a genetic abnormality or
inherited disease, as well as, the lessened chance of a couple being faced with the
decision of pregnancy termination (Fragouli, 2007). However, there are risks associated
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with PGD. Embryo biopsies may damage or destroy embryos, requiring that
embryologists and laboratory technicians performing embryo biopsy are highly skilled
(Baruch et al., 2008). Removal of a cell from an embryo may also decrease implantation
rates (Baruch et al., 2008). According to Baruch, “in all cases of PGD, it is critical to
know whether the positive effect of selecting “normal” embryos or those with the desired
trait is worth the risks and potentially detrimental effect of removing a cell for
analysis” (Baruch et al., 2009, p. 250).
With newer advancements in genetic diagnostic technology, the uses of PGD have
expanded dramatically, and some of these newer uses are controversial. Many
individuals in the research, bioethics, and medical communities are concerned that nonhealth-related traits or “positive traits” such as intelligence or athleticism could be
selected for in the future. Yet not all disease or non-health-related traits have an
identified gene (Baruch et al., 2008). Often, “positive traits” are associated with multiple
genetic and environmental factors and cannot be identified through current genetic testing
technologies. Therefore, at the current time, parents are unable to select every
characteristic or trait of their future child(ren). Preimplantation genetic diagnosis is also
unable to create new traits that do not otherwise exist in the parents. PGD does not
involve “genetic manipulation or “engineering” of the embryo itself” (Baruch et al.,
2009, p. 250).
1.3 Current Applications of PGD
There are numerous reasons why couples may choose PGD testing. These
reasons include, but are not limited to: sex selection, a previously affected pregnancy/
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child, human leukocyte antigen (HLA) matching, one member of a couple is affected
with a genetic condition or carries a balanced chromosomal rearrangement, advanced
maternal age, and to increase the effectiveness of IVF by ruling out chromosomal causes
of miscarriage and failed embryo implantation (Chang et al., 2011).
Initially, PGD was only used to identify embryos at risk for childhood-onset,
single gene disorders. Single gene disorders are caused by mutations in a specific gene;
examples include cystic fibrosis, sickle cell disease, hemophilia and Marfan syndrome.
In principle, PGD, is able to identify the same single gene disorders tested for by prenatal
diagnosis (Chang et al., 2011). In order for PGD to be performed for single gene
disorders, a known disease-causing mutation must have been identified in the family
(Handyside, Lesko, Tarin, Winston, & Hughes, 1992).
In the early 1990s, researchers attempted, for the first time, to identify embryos
with cystic fibrosis using PGD (Handyside et at., 1992). Cystic fibrosis is an autosomal
recessive condition common in the Caucasian population, with an incidence of one in
2500 live births and a carrier frequency of one in 25. A mutation in the cystic fibrosis
transmembrane regulator (CFTR) gene causes defective chloride ion transport, which
leads to multiple medical complications affecting several organs including the lungs and
pancreas (Cant, Pollock, & Ford, 2014). In the study by Handyside et. al. (1992), three
couples, all carrying the common delta F508 mutation in the CFTR gene, requested PGD
to prevent the birth of children with cystic fibrosis. Each couple had at least one
previously affected child with cystic fibrosis and wished to avoid another affected child
or pregnancy termination after prenatal diagnosis. Couples were counseled about the
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risks of the procedures and understood that, at the time, this was still an experimental
treatment (Handyside et at., 1992). Using polymerase chain reaction (PCR), researchers
amplified the CFTR gene from single cells removed from the couples’ embryos and
identified non-carrier, carrier, and affected embryos. In one couple, a non-carrier embryo
and a carrier embryo were both transferred on the same day of DNA analysis. A
pregnancy resulted and a female child was born, free of the parental mutations and
therefore unaffected by cystic fibrosis. Another couple also transferred both a carrier
embryo and a non-carrier embryo; however, no pregnancy resulted. A third couple did
not undergo embryo transfer as none of their embryos were identified as free of the
mutation (Handyside et at., 1992).
Some couples may choose to pursue PGD to select embryos that are a human
leukocyte antigen (HLA) match for a sibling in need of a bone marrow transplant. An
HLA matched embryo allows for allogeneic haematopoietic stem cell (HSC)
transplantation through cord blood or bone marrow donation from a healthy sibling to
one who is ill (Pennings, Schots, & Liebaers, 2002). In some conditions, a stem cell
transplant from an HLA matched sibling is often the only cure (Pennings et al., 2002).
In 2001, the first case of PGD for an HLA matched sibling was successful for
Fanconi anemia. Fanconi anemia is an autosomal recessive condition that causes a
multitude of congenital anomalies and developmental issues, and most affected
individuals have a significantly shortened life span due to bone marrow failure and a
significantly increased risk of developing leukemia (Kupfer, 2013). Although many
anomalies in Fanconi anemia may persist, the bone marrow failure and high risk for
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leukemia may be successfully treated with a cord blood or bone marrow transplant. The
success rate of a bone marrow transplant to treat Fanconi anemia is significantly greater
when the donor is an HLA matched sibling to the recipient. When testing an embryo for
HLA matching, testing for a single gene disorder can also be done at the same time to
ensure that the embryo is also free of the genetic condition (Milachich et al., 2013). In
this first case, researchers were able to successfully identify and transfer embryos that
were unaffected with Fanconi Anemia and were also an HLA match to the affected
sibling (Verlinsky, Rechitsky, Schoolcraft, Strom, & Kuliev, 2001). A healthy, HLA
matched baby was born to this couple, and a successful bone marrow transplant was later
performed on the affected child using umbilical cord blood collected from the newborn at
the time of delivery. Preimplantation genetic diagnosis has been used effectively for this
purpose in similar situations, such as β-thalassemia, and severe combined
immunodeficiency (SCID) (Milachich et al., 2013).
Another frequent indication for PGD is a balanced chromosomal rearrangement in
one parent, such as an inversion or translocation (Alfarawati, Fragouli, Cools, & Wells,
2011). Balanced chromosomal rearrangements are the basis of recurrent miscarriages in
five to 10 percent of couples (Vanneste et al., 2011). Individuals who carry a balanced
chromosome rearrangement are typically healthy but can produce unbalanced gametes.
Embryos with unbalanced rearrangements often fail to implant or result in miscarriage,
and therefore, couples in which one partner carries a balanced rearrangement are at
increased risk for infertility and/or recurrent miscarriage. If a live birth with an
unbalanced rearrangement does occur, there are often birth defects, developmental
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delays, and/or intellectual disabilities (Chang et al., 2011). Alternatively, those who
inherit balanced rearrangements from a parent, with no extra or missing genetic
information, are not usually at increased risk for spontaneous abortion or developmental
problems (Chang et al., 2011). For carriers of balanced rearrangements, PGD to select
against embryos carrying unbalanced chromosome rearrangements can reduce
spontaneous abortion, minimize the risk of offspring inheriting a chromosome imbalance,
and increase pregnancy rates (Vanneste et al., 2011).
Preimplantation genetic diagnosis can also be used to select against conditions
that usually do not manifest until adulthood, such as Huntington’s disease or early-onset
Alzheimer’s disease. Huntington’s disease is an autosomal dominant neurodegenerative
disorder affecting muscle control, cognitive functions, behavior and personality (Lee,
Hwang, Hun, Kowall, & Ryu, 2013). The majority of cases experience symptoms
between the ages of 30 and 50 years old. Alzheimer’s disease is another adult-onset,
irreversible, progressive brain disease. Most cases of Alzheimer’s disease occur after the
age of 60, but there is also an early onset, monogenic form (Verlinsky et al., 2002).
The first use of PGD for early-onset Alzheimer’s disease occurred in the early
2000s. Three genes associated with this form of Alzheimer's disease are presenilin one
(PSEN1), presenilin two (PSEN2), and amyloid precursor protein (APP) (Verlinsky et al.,
2002). Mutations in these genes predispose a person to developing Alzheimer’s disease.
Penetrance has not been established for all three genes, but mutations in the APP gene are
known to be almost completely penetrant (Verlinsky et al., 2002). In one case, a 30-year
old female requested PGD because she carried a familial mutation in the APP gene.
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Embryos without the familial mutation were identified and transferred. A pregnancy was
successfully established and verification of an unaffected fetus was obtained through
CVS. This case demonstrates the feasibility of using PGD for adult-onset predisposition
genes, for conditions like Alzheimer’s disease (Verlinsky et al., 2002).
1.4 Practice Guidelines in the Utilization of PGD
Preimplantation genetic diagnosis has several uses that push bioethical boundaries
and thus are considered controversial. For this reason, in many countries, there are
professional organizations that provide guidance regarding the use of PGD. These ethics
committees include the Human Fertilization and Embryology Authority (HFEA) in the
United Kingdom, and the American Society for Reproductive Medicine (ASRM) in the
United States. Both committees have published guidelines regarding use of PGD. It is
important to distinguish that the HFEA influences laws governing the use of PGD, versus
ASRM which develops guidelines for healthcare providers. There are no laws governing
PGD in the United States, which is different from the United Kingdom. American
physicians can choose to implement or ignore guidelines, whereas British physicians are
mandated by laws developed from HFEA regulations.
In the United Kingdom, the HFEA is the governing authority regarding the use of
gametes and embryos in research and fertility treatment. The HFEA determines the
conditions for which PGD can be used and grants licenses for each condition
(Ormondroyd et al., 2012). According to the HFEA website, as of 2012, the HFEA
allows for PGD to be performed for more than 350 genetic conditions. Decisions
regarding which conditions are allowed are guided by three ethical principles (Williams,
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Ehrich, Farsides, & Scott, 2007). First, the individual seeking PGD must feel that a
condition is serious enough to cause them concern. Second, there should be a significant
risk that an embryo will have a serious genetic condition. Third, indications for PGD
should be similar to current practices in prenatal diagnosis (Williams et al., 2007). When
deciding which diseases can be tested by PGD, the HFEA also considers the suffering
experienced by the affected individual and if there are effective treatments available. In
2006, HFEA supported “widening the scope for PGD to include susceptibility to late
onset, lower penetrance conditions” (Williams et al., 2007, p. 1095).
In the United States, the American Society of Reproductive Medicine (ASRM),
has published several committee opinions regarding the use of PGD. The ASRM
recommends that couples considering PGD should receive genetic counseling. Genetic
counselors who handle PGD cases must relay to each couple information relating to risks
associated with IVF, risks associated with biopsy and culture of embryos, inheritance,
quality of life, possibility of misdiagnosis, prenatal diagnostic testing, the possibility that
all embryos are affected, and alternative methods of avoiding disease (Practice
Committee of the American Society for Reproductive Medicine, 2008).
Regarding PGD for adult-onset conditions, ASRM concludes that PGD is
ethically justified when a condition is serious and there are no safe and effective
treatments available. As a matter of reproductive liberty, ASRM also advocates for the
ability to use PGD for less serious or lower penetrance conditions. In the case of a single
gene disorder, ASRM states that PGD is a significant advance over prenatal diagnosis and
pregnancy termination (Ethics Committee of American Society for Reproductive
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Medicine, 2013). With regards to sex selection, ASRM concludes that PGD should only
be allowed to prevent sex-linked genetic conditions from being transmitted and not as a
means of family balancing (Ethics Committee of American Society for Reproductive
Medicine, 2013).
Although ASRM has published many committee opinions regarding the use of
PGD, there are several recently evolved uses of PGD that have yet to be addressed with
practice guidelines. These include: PGD for a variant of unknown significance and use of
embryos with genetic disease after PGD revealed no disease-free embryos to be
available.
1.5 Controversial Applications of PGD
1.5.1 Adult-onset Disorders. PGD for couples whose offspring are at risk for adultonset conditions has raised concerns as these conditions do not occur until later in life.
Approximately 28% of fertility clinics that responded to a 2005 survey reported that they
have provided PGD to avoid serious adult-onset diseases (Baruch et al., 2008). Many
factors determine what conditions are “serious” including severity of symptoms,
penetrance, potential for treatment, disease progression, heritability, and age of onset
(Krahn, 2009).
The use of PGD to avoid offspring who have inherited mutations that predispose
to diseases and are incompletely penetrant is also controversial. For example, mutations
in the BRCA1 and BRCA2 genes can confer predisposition to certain cancers but do not
guarantee that cancer will occur (Ormondroyd et al., 2012). In women, mutations in
these genes confer a lifetime risk of up to 87% for developing breast cancer and up to a
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44% lifetime risk of developing ovarian cancer. Men who carry mutations in these genes
have an increased risk of breast and prostate cancer. Prior to 2006, HFEA only licensed
conditions that had close to 100% penetrance, meaning individuals who had a mutation
were nearly 100% likely to develop the disorder. In 2006, the HFEA expanded its list of
approved PGD uses to include cancer predisposition genes, including BRCA1 and BRCA2
(Ormondroyd et al., 2012). According to the HFEA, “in principle, it is appropriate that
PGD be available for serious, lower penetrance, later-onset genetic conditions such as
inherited breast, bowel, and ovarian cancer” (Krahn, 2009, p. 189). Although some
adult-onset conditions, such as breast cancer, can be successfully treated and are not
necessarily fatal, the HFEA identifies them as “serious genetic conditions because they
cause suffering and are life threatening,” and determines that “PGD should be available
to test for these cancers” (Krahn, 2009, p. 189).
1.5.2 Variant of Unknown Significance. A more recent development in the use of
PGD comes from patient requests for selection against a genetic variant of unknown
significance (VUS). A VUS is a deletion, duplication, or nucleotide sequence change that
has not been previously defined as deleterious and can be either inherited or de novo. A
genetic change categorized as a VUS has not been defined as clinically significant or
predictive of an individual’s phenotype. For individuals that have inherited a VUS,
clinical significance and recurrence risk are often difficult to elucidate because of
unknown factors such as variable expressivity and incomplete penetrance (Reiff et al.,
2012).

!13

This is another controversial issue faced by the PGD community, as it is not
definitively known if a VUS is disease causing. There is little published information
about the experience of PGD laboratories in terms of testing for these variants. However,
according to a genetic counselor at Reproductive Genetics Institute (RGI) in Chicago,
there are increasing requests for selection against a VUS in both situations where the
VUS is believed (but not proven) to be disease causing, or where there is a significant
degree of uncertainty surrounding a particular genetic disease (Besser, 2013). One such
disease is Marfan syndrome.
The first reported clinical use of PGD to avoid the inheritance of Marfan
syndrome occurred in the mid 1990s (Harton et al., 1996). Marfan syndrome is an
autosomal dominant connective tissue disorder, which mainly affects the skeleton, eyes
and cardiovascular system (Coron et al., 2012). There is a wide range of phenotypic
variability, and while some individuals have severe involvement of multiple organ
systems, mildly affected individuals can remain undiagnosed for their entire lives without
major health concerns (Harton et al., 1996). Preimplantation genetic diagnosis is usually
feasible if a known pathogenic mutation in the FBN1 gene is identified. However, most
mutations in the FBN1 gene are private, and therefore molecular sequencing of this gene
often identifies a VUS. Given the uncertainty surrounding a VUS and whether it is truly
causing a patient’s clinical diagnosis of Marfan syndrome, it is often difficult to counsel
patients about what this result can mean for future children. Performing PGD for a VUS
for Marfan syndrome does not guarantee that a child will not have Marfan syndrome,
since it is possible that another pathogenic mutation exists but is unidentifiable with
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current technologies. Therefore, the appropriateness of PGD or prenatal diagnosis for a
VUS is questionable, and with the increasing availability of multigene sequencing panels
and whole exome/genome sequencing, is likely to become a frequent and significant
issue in the field.
1.5.3 Use of embryos with genetic disease after PGD revealed no disease-free
embryos to be available. Another controversial use of PGD is use of embryos with
genetic disease after PGD reveals no disease-free embryos. Some couples deliberately
select for a child with a genetic condition typically because at least one member of the
couple has that disorder, like deafness or dwarfism (Baruch, 2009). For example, a
woman with achondroplasia may choose to implant embryos with the disorder because
her small physical stature would affect her ability to carry an average size baby. Several
PGD laboratories have stated that individuals seeking to use PGD to intentionally select
for diseases or disabilities would not be offered PGD (Baruch, 2009). However, it is
possible that during the PGD process, no healthy embryos are available for transfer. In
this situation, patients want a healthy child but do not have healthy embryos for transfer.
Couples must then choose whether or not to start over or use one of the affected embryos.
1.6 Ethical Considerations For The Use of PGD
Although a valuable and useful technique, PGD has ethical challenges associated
with its uses. Currently, there is much debate regarding the appropriate parameters for
the use of PGD (David, Weitzman, Herve, & Fellous, 2012). There is also discussion
regarding whether PGD is “an obligation or good practice” (David et al., 2012, p. 625).
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Some argue that “it is time to recognize that impairments occur along a
continuum” (Miller & Levine, 2013, p. 100). On one end of this continuum there are
conditions such as congenital deafness, which may not have a significant impact on
health or life expectancy. On the other end of the spectrum, conditions like Tay-Sachs
disease cause significant suffering and a shortened lifespan. It is argued that “value
judgments regarding the quality of life of a person with a given disability must be made
by the individual who lives with the disability, not by the researcher or clinician” (Miller
& Levine, 2013, p100). Many individuals with disabilities and/or genetic conditions
have found their lives to be fulfilling and valuable. The disability community has
expressed concern about the intention and outcomes of genetic research; specifically,
whether advances in genetic diagnostic technologies are intended to eliminate disability
from the population. Specifically, PGD is seen negatively by some members of the
disability community, as its intention is to prevent the birth of individuals with disability
(Miller & Levine, 2013). Some equate this concern to the notion that there will be lower
tolerance for individuals with disabilities, as well as increased injustice, stigmatization,
and discrimination (Vergeer et al., 1998; Petersen, 2005). For these reasons, some people
in the disability community are wary of PGD and see it as a misuse of genetic
technology.
Others would argue that selection of embryos with a genetic condition is not
the intended use of PGD, and that this technology is only intended to prevent the
transmission of genetic diseases to future generations. While PGD was not designed to
select for children with diseases or disabilities, a survey performed in 2005 by Baruch et
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al. found that three percent of fertility clinics reported having used PGD to select for a
particular disease or disability. In all cases, the conditions selected for were forms of
deafness or dwarfism (Baruch et al., 2008).
There are arguments that parents have the moral and ethical responsibility to
select embryos that have the “best chance in life,” and therefore, embryos with a known
genetic condition should not be selected for implantation. Other factors to take into
account when examining the ethics of reproductive decision-making include procreative
autonomy and non-directive counseling (Savulescu, 2001).
The basis of procreative autonomy is that couples are free to decide what kind
of children to have, as well as when and how to have these children, even if that means
they are selecting for a disability. According to the principle of non-directive counseling,
medical personnel should provide patients with information about risks and options to
reduce these risks. Specific advice or direction should not be given to patients. This
principle argues, for example, that if a couple knowingly chooses to transfer an embryo
that is affected with a genetic disease, then the medical professional should not express
agreement or disagreement about this decision (Savulescu, 2001).
Some bioethicists argue that children have a right to an “open future” and if
their parents choose to “unreasonably limit the life plans available to their child, the child
suffers a moral harm” (Smolensky, 2008, p. 3). However, what if prospective parents feel
as though they have no other choice because all of their embryos are affected with a
genetic condition? According to some, there is a difference between choosing an embryo
with a genetic predisposition when you have the option of another healthy embryo with
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the “best” chance, and choosing an embryo with a genetic predisposition only because
there are no “healthy” embryos. The question becomes, should couples be able to use an
affected embryo if no healthy ones are available?
The goal of PGD is to produce healthy offspring by not implanting embryos
that are affected with a known disease. In the United States, the use of PGD is often
determined by the IVF clinics and PGD laboratories. Although there are professional
guidelines to assist with decision-making, these guidelines do not address all possible
scenarios that may arise. As there are no regulations regarding the use of PGD, many
genetic counselors and other IVF/PGD providers continue to face the ethical dilemmas
described.
1.7 Need for Current Study
The purpose of this study is to explore the opinions and attitudes of genetic
counselors who work with patients throughout the PGD process. Another purpose is to
determine common themes identified by genetic counselors regarding three controversial
PGD case scenarios: PGD to select against an adult-onset condition, use of embryos with
genetic disease after PGD revealed no disease-free embryos to be available, and PGD to
select against a variant of unknown significance (VUS). The information gained from
this study will add perspectives from genetic counselors who work with PGD patients to
the discussion concerning controversial applications of the technology. Interviews will
provide a more detailed description of ethical challenges experienced by genetic
counselors and help professional organizations properly guide the use of PGD.
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Chapter 2: Walking the Edge with Controversial Use of Preimplantation Genetic
Diagnosis (PGD): Opinions and Attitudes of Genetic Counselors1
2.1 Abstract

!

Purpose: This study explored opinions and attitudes of genetic counselors regarding
three controversial applications of preimplantation genetic diagnosis (PGD): PGD for
early-onset Alzheimer, use of embryos that are BRCA positive after PGD revealed no
disease-free embryos to be available, and PGD to select against a variant of unknown
significance (VUS) for Marfan syndrome. Methods: Genetic counselors were contacted
through the National Society of Genetic Counselors (NSGC) electronic mailing list.
Inclusion criteria required that a participant was currently practicing as a genetic
counselor, was a member of the NSGC, and has counseled patients about PGD. Twentynine participants volunteered to participate and 24 recorded interviews were transcribed
for data analysis. The survey consisted of 34 questions including demographic questions,
qualitative questions about each of the three case scenarios, and general questions about
PGD. Qualitative analysis was performed using a conventional content analysis approach
as described by Hsieh (2005). Results: Themes common to all three scenarios included:
necessity of appropriate/thorough counseling, the importance of the genetic indications,
patient perceptions, and respect for patient autonomy in decision making. Multiple
themes were also described for each unique case scenario. The majority (65%,15/23) of
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participants felt PGD for an adult-onset disorder was least controversial, and PGD for a
VUS was most controversial. Conclusion: Participants felt that PGD was appropriate for
life limiting conditions, cases where there was an established diagnosis with a known
pathogenic mutation, and when symptom severity and disease burden were significant.
Participants agreed that appropriate/thorough counseling was necessary, patient
perceptions of ‘serious’ disease were critical, and patient autonomy were key factors
when dealing with controversial applications of PGD. Ultimately, genetic counseling is
recommended and patients need to understand the benefits, disadvantages, and the
potential outcomes of PGD in order to make the decision that is most appropriate for their
families.
Keywords: Preimplantation genetic diagnosis (PGD), controversial, genetic
counselors’ opinions.
2.2 Introduction
Since the 1990s, preimplantation genetic diagnosis (PGD) has been used to
prevent genetic disorders from being inherited by future generations. Individuals who
carry a known genetic mutation or chromosome rearrangement can use PGD to identify
embryos at risk of inheriting a genetic condition. Indications for PGD include, but are
not limited to: sex selection, a previously affected pregnancy/child, one member of a
couple is affected with a genetic condition or both carry an autosomal recessive mutation,
and to increase the effectiveness of IVF by ruling out aneuploidy, chromosomal causes of
miscarriage and failed embryo implantation (Hershberger & Pierce, 2010; Chang et al.,
2011). However, given the advancements in genetic testing and expansion of knowledge
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in the field of genetics, PGD has been used for other indications, some of which are
controversial.
Professional guidelines from the American Society of Reproductive Medicine
(ASRM) and the Human Fertilization and Embryology Authority (HFEA) explicate
appropriate utilization, yet these guidelines do not address all possible scenarios that may
arise. Therefore, many genetic counselors and other IVF/PGD providers continue to face
ethical dilemmas.
Here we discuss the opinions of genetic counselors regarding three controversial
uses of PGD: (1) PGD for early-onset Alzheimer, (2) transferring male embryos which
carry a BRCA1 mutation when no unaffected embryos are produced, and (3) PGD for a
variant of uncertain significance (VUS) for Marfan syndrome.
2.3 Materials and Methods
2.3.1 Participants. After receiving Institutional Review Board approval from the
Office of Research Compliance, University of South Carolina, Columbia, SC, an
invitational letter (Appendix A) was sent through the National Society of Genetic
Counselors (NSGC) electronic mailing list to genetic counselors, inviting their
participation in our study. The inclusion criteria required that a participant was currently
practicing as a genetic counselor, had counseled patients regarding the use of PGD, and
was a member of the NSGC. The Assisted Reproductive Technologies and Infertility
Special Interest Group (ART/Infertility SIG) of the NSGC also forwarded an invitational
letter to its members.
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2.3.2 Research Methods. Individuals who responded to the invitational letter were
asked for their verbal consent (Appendix B) before accruing into the study and
proceeding with the survey (Appendix C). Consenting participants were interviewed by
telephone and all interviews were recorded to maintain the veracity of the data. The
survey consisted of 34 questions and required 25 to 45 minutes to complete (see
Appendix C). Six demographic questions were followed by qualitative, semi-structured,
open ended questions about each of the three case scenarios (21 questions), and general
questions about the use of PGD (7 questions). No identifying information was collected.
The survey questions were used to assess participants’ opinions and attitudes about each
case scenario and their opinions on controversial uses of PGD technology.
2.3.3 Statistical Analysis. The audio recorded interviews were transcribed and verified
for accuracy by the principal investigator (first author). Qualitative analysis was
performed using a conventional content analysis approach as described by Hsieh &
Shannon (2005). This approach allows for the identification and coding of data that
reflects the participants’ views and opinions of the scenarios presented. During the
analytic process, patterns emerged from the codes and were classified into categories.
The categories formed the basis for emergent themes and sub-themes. An advantage of
conventional content analysis is that it gains “direct information from study participants
without imposing preconceived categories or theoretical perspectives” (Hsieh &
Shannon, 2005, p. 1279-1280). Thus, this analytic method was selected for our study
because it identifies themes that are intended to help understand participants’ unique
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perspectives. Consistent with content analysis, frequency counts were performed, when
appropriate, during data analysis.
2.4 Results
Twenty-nine participants volunteered for the study; two participants were
excluded as they did not meet inclusion criteria. Three audio recordings were unusable;
therefore, a total of 24 recorded interviews were transcribed and used for data analysis.
2.4.1 Demographic Data. Table 2.1 shows the distribution of participants’ gender, age,
years of practice as a genetic counselor, number of years they have counseled for PGD,
number of PGD cases seen per month, setting of practice, and region of practice. The
large majority of participants were women, 96% (23/24). Most participants were
between the ages of 25 and 30 years of age, 42% (10/24), and had less than one year to
five years of experience practicing as a genetic counselor (54%, 13/24). Fifty-four
percent (13/24) had been counseling for PGD for zero to five years and 42% (10/24)
typically counsel for PGD one to five times a month. Six of the 24 participants counsel
greater than 20 PGD cases a month. The largest group of participants indicated that they
were working in settings other than reproductive endocrinology clinics or PGD
laboratories, 54% (13/24). These settings included maternal fetal medicine clinics,
pediatric clinics, and adult clinics. Twenty-five percent (6/24) indicated they worked in a
PGD laboratory setting and 21% (5/24) indicated they worked in a reproductive
endocrinology setting.

!
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Table 2.1
Demographics
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Demographic

% of Participants

Number of Participants

4.2%
95.8%

1
23

4.2%
41.7%
16.7%
12.5%
16.7%
8.3%

1
10
4
3
4
2

54.2%
12.5%
16.7%
4.2%
8.3%
4.2%

13
3
4
1
2
1

8.3%
54.2%
20.8%
12.5%
4.2%

2
13
5
3
1

16.7%
41.7%
8.3%
4.2%
4.2%
8.3%
8.3%
8.3%

4
10
2
1
1
2
2
2

25%
20.8%
54.2%

6
5
13

20.8%
25%
4.2%
25%
8.3%
16.7%

5
6
1
6
2
4

Gender
Male
Female
Age
< 25
25-30
31-35
36-40
41-50
> 51
Number of years in practice as a genetic
counselor
0-5
6-10
11-15
16-20
21-25
>25
Number of years participants have
counseled for PGD
<1
1-5
6-10
11-15
16-20
Number of all PGD cases seen per month
<1
1-5
6-10
11-15
16-20
21-30
> 30
> 50
Setting of Practice
PGD Laboratory Setting
Reproductive endocrinology
Other
Region of Practice
Region 1
Region 2
Region 3
Region 4
Region 5
Region 6
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2.4.2 Conventional content analysis. Conventional content analysis was used to
analyze data obtained from recorded interviews. Themes and key words were identified
from answers given by each of the 24 participants and quotes were used to illustrate and
support the identified themes. Frequency counts were also used for certain questions.
2.4.3 PGD for an adult-onset condition. For PGD for early-onset Alzheimer’s
disease, participants were first asked if this scenario raised any concerns for them, and if
so, what concerns were raised. Of the 24 participants, 58% (14/24) stated that PGD for
this reason raised no concerns and 43% (6/14) of those participants were not concerned
because of patient autonomy. From those 14 participants, 21% (3/14) stated they were
comfortable offering PGD for any adult-onset condition including early-onset Alzheimer.
Forty-six percent (11/24) of participants raised several concerns. Several themes
emerged, including: effects on counselors’ comfort, psychosocial topics, and autonomy of
the child and spouse.
2.4.3.1 Effects on counselors’ comfort levels.
Necessity of appropriate/thorough counseling
Several commonly shared concerns regarding PGD for adult-onset conditions
were noted. For 17% (4/24) of the counselors interviewed, the specific mutation in the
discussed scenario predisposed, but did not guarantee, a person to have early onset
disease. Therefore, penetrance of the condition affected counselors’ comfort levels of
using PGD:

!
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“I think one of my main concerns is whether it is one of those conditions for
which having the mutation is a given to getting the diagnosis or it is a predisposing factor so those conditions that PGD would be used to detect
predisposition I think are a little harder to swallow ethically than those which the
mutations kind of equals the disease state at some point” (S)
“I think that if it were a highly penetrant mutation, my concerns would be
lessened…” (B).
Having a known mutation influenced 13% (3/24) of participants’ comfort level for
offering PGD:
“It doesn’t raise any significant concerns for when there is a clear genetic cause
that leads to an increased risk for an adult-onset condition such as early onset
Alzheimer…” (K)
“I think people should be able to do this for any reason that they choose as long
as there is evidence to support that it should be done…” (F).
If patients choose to pursue PGD for an adult-onset condition, 29% (7/24) of
participants agreed that it is the patient’s right:
“I don’t feel that it is my place as a counselor to tell that couple that they
couldn’t use it…” (W)
“I just try and let my patients make the choice that’s right for them” (C).
Three participants (13%, 3/24) wanted patients to understand that otherwise healthy
embryos could be discarded and potentially their could be future treatments:
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“Part of the genetic counseling for PGD is making sure that the couple is aware
of the implications of discarding otherwise healthy embryos” (N)
“A potential concern would be the possibility of anything adult-onset, is will
treatment become available by the time a potentially affected child would be born
and have and be at risk for this” (Q).
2.4.3.2 Psychosocial Topics. Twenty-one percent (5/24) of participants considered the
patient’s perception of which conditions were “serious enough,” concerning, or
burdensome as important and 20% (1/5) of these participants considered PGD an
opportunity to spare the child:
“Ultimately is that something that the patient wanted to do and felt that it was
important enough…I would continue to counsel them appropriately” (B)
“What I always try to tell my patients to think about is how burdensome has this
disease been in your own life…for some patients it feels like a huge huge burden
to know that this is coming later down the road and for them the idea of being
able to spare that for their child is a really big gift” (C)
“I think that if it’s concerning for the couple and they want to choose to avoid a
pregnancy that is at risk for early-onset Alzheimer then they can…” (E).
Concern for the family
Eight percent (2/24) of participants were concerned that PGD for this reason,
undervalued the life of the patient and other affected family members:
“Just because they’ll have Alzheimer let’s say at 55, doesn’t mean that they might
not win a Nobel Prize at 40…” (N)
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“I would be concerned that the parent is undervaluing their life or the life of
their family that had been affected with the disorder” (A).
Eight percent (2/24) of participants stated children would not exhibit symptoms for many
years and if a laboratory error occurred and an affected embryo were transferred, the
child’s autonomy would be violated. In total, 13% (3/24) of participants were concerned
about the potential child’s autonomy:
“The pre-child, the un-conceived child… can’t consent to that testing…we don’t
have a fetus yet and the whole point is to avoid having a fetus who would have
the gene…it is kind of semantic on one level but I see it on both as if there is not
yet a person who would not need to consent…” (U).
Participants were next asked how they felt about PGD to identify embryos at risk
for early-onset Alzheimer’s disease. The two themes that emerged were: comfortable and
patient autonomy.
2.4.3.3 Comfortable. The majority of participants (83%, 20/24), were comfortable with
PGD for this use; however, 60% (12/20) still had concerns, including: necessity of
appropriate/thorough counseling, penetrance, patient’s perceptions, and propriety of this
use of PGD. Thirty-five percent (7/20) of the comfortable participants agreed this was an
appropriate use of the technology: “If it is something that is important to the patient then
I think that’s a valid use of the technology” (C).
2.4.3.4 Patient autonomy. Eight percent (2/24) of participants were not comfortable
using PGD in this situation but would support the family regardless. Fifty percent (1/2)
of those participants were concerned that a PSEN1 mutation was not 100% penetrant and
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this was not an ideal use of the technology (2/24), however, they would support the
patient as long as appropriate counseling occurred (3/24):
“I feel kind of unhappy about that…I think a lot of what it comes down to is the
level of education provided to the couple I think. And I feel pretty strongly in
general that if they really have a good handle on what the limitations of the
testing are and they understand …that it would be a predisposition, it would not
be a given, and they still maintain that they are still really interested in pursuing
it then I would be more comfortable” (S)
“The biggest concern with that [BRCA mutations] could be discarding an
embryo that while it carries the mutation a person may never have actually had
cancer” (Q).
Fifty percent (12/24) agreed they would support the patient’s decision and 33% (4/12)
stated the patient should determine if the condition is “serious enough”:
“For someone that watched a family member die from early-onset Alzheimer I
can see why they would want to prevent having a child with it…so that they can
give their child a better life. You know I feel like that is a completely unselfish
reason to do PGD because it is not helping them at all because they probably will
not live to see their child diagnosed with it. They are ensuring that their child
will not get early onset Alzheimer” (B)
“That particular family knows the disease better than anybody else. And if they
feel that the disease is, you know, it is bad enough to warrant PGD and embryo
testing then you know that is their decision” (D)
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“I do not have a problem…because I care more about what the patient thinks
than what I think. And I think that the patient’s concerns given her life
experience, given her family experience that she is deciding for her own children,
I am on board” (H).
Eight percent (2/24) of participants believed that even though this is an option for
patients, it was not necessarily the most ideal use of PGD: “I feel that while it might not
be the ideal use of PGD it’s certainly not the worst use of PGD” (M).
Participants were asked about previous experiences counseling PGD cases for
adult-onset conditions. Twenty-five percent (6/24) have never counseled patients about
PGD for adult-onset disorders, versus 75% (18/24) had previous experience with such
cases. Of the participants with experience (75%, 18/24), 56% (10/18) have had cases of
Huntington’s disease and 5 of those 10 participants (50%), have also counseled for cancer
predisposition syndromes (i.e. Lynch syndrome, FAP, and BRCA1/2). In total, 67%
(12/18) have counseled for cancer predisposition syndromes, 50% (6/12) of those that
have counseled for cancer syndromes have not counseled other adult onset disorders.
One participant (6%, 1/18) counseled a single patient about PGD for Alzheimer’s disease.
Regarding participants’ experiences counseling about PGD for adult-onset
disorders, participants were asked about their concerns. Of the 18 participants with
experience, 33% (6/18) had no concerns and 67% (12/18) had concerns. From this data
we established the following themes: non-disclosure/ exclusion testing and necessity of
appropriate/thorough counseling.
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2.4.3.5 Non-disclosure/ Exclusion testing. Fifty percent (5/10) of the individuals who
have counseled about PGD for Huntington’s disease were concerned about nondisclosure testing and 60% (3/5) of those participants were concerned patients might
accidentally learn their mutation status:
“My biggest concern was for the non-disclosure Huntington patients. Patients
who themselves did not want to know their status but still wanted to do PGD to
make sure their kids didn’t have it. And I felt there was a lot of psychosocial
things that could be explored with those patients” (A)
“My primary concern is that we were going to blow it somehow and we were
going to give her, you know her results” (F)
“There is still a test result out there and even though the lab and whoever is
involved would do anything it can to make sure that information is not released,
certainly there are instances where mistakes can happen” (T).
Twenty-five percent (3/12) of participants were uncomfortable with discarding healthy
embryos after exclusion testing for Huntington’s disease or carriers of cancer
predisposition gene mutations: “You might be discarding embryos that are completely
unaffected” (T).
2.4.3.6 Necessity of appropriate/thorough counseling. Adult-onset conditions are
complex and psychosocially challenging for couples and counselors. Sixty-seven percent
(8/12) of participants felt appropriate counseling was crucial when dealing with such
cases:
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“As long as the family or the couple is appropriately counseled about, the
benefits and limitations of the technology and really understands the ins and outs
and understands they are not using embryos that other than developing
Alzheimer at an earlier than expected age but can have an otherwise, healthy life
as long as they understand all of those aspects then I think they have the decision
to make the reproductive choice that makes the most sense to them” (Q).
Seventeen percent (2/12) of participants said PGD prevents suffering for future
generations; although one of the two participants stated patients need to understand that
risk to a potential child is not completely eliminated, as well as the potential for
treatments to become available in the future:
“So I think in those cases [cancer predisposition syndromes] we felt like it was
definitely a good reason to prevent suffering in a person down the road” (S)
“She was not interested in having her children necessarily be…having to go
through that knowing that they already would probably have to deal with her
health issues” (V)
“We talked about the concerns that it’s not going to eliminate the risk of cancer
and there could be…they could have a PTEN mutation and we didn’t test for
that” (V).
“I think that one [BRCA] is a little bit trickier for people because unlike
Huntington’s there are actually things you can do to help prevent or reduce the
risk of cancer…because that is something that there is at least some action that
you can take I think that one is a little bit harder for people to understand” (T).
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Lastly, participants were asked how comfortable they were offering PGD for any
adult-onset condition. On a scale of one to five, where one was not comfortable at all and
five was very comfortable, the majority of participants, rated themselves as a four (38%,
9/24) or five (33% (8/24) (see Figure 2.1).
2.4.4 Use of embryos with genetic disease after PGD revealed no disease-free
embryos to be available. Participants were asked if they had any concerns regarding the
transfer of a male embryo that carries a BRCA1 mutation when no unaffected embryos
were produced. Themes that emerged from discussion were: necessity of appropriate/
thorough counseling, patient autonomy, and implications of gender selection.
2.4.4.1 Patient autonomy. Forty-two percent (10/24) understood couples’ reasoning for
transferring a male carrier because the risk of cancer is less in a male. Forty-two percent
(10/24) agreed that it is the patient’s choice and 60% (6/10) of those 10 felt that couples
were making a well informed decision. One individual (4%, 1/24) was worried about the
autonomy of the child since his genetic status would be known from birth:
“They have completely eliminated that person’s decisions of whether or not to do
testing as an adult. So I would be curious, I would want to explore with the
parents about are they planning on telling their son this information and I do not
know what the right answer to that questions is….you are also leaving that son
with having to make the same decisions when he becomes of child bearing
age” (V).
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2.4.4.2 Necessity of appropriate/thorough counseling. Twenty-five percent (6/24) of
participants had no major concerns and 50% (3/6) of those stated couples were choosing
the “less risky” sex. Twenty-nine percent (7/24) of participants were concerned the
potential male child’s future children are now at risk of inheriting the mutation and 86%
(6/7) of those seven participants agreed couples need appropriate counseling to be fully
informed of the long term ramifications of transferring a male with a BRCA1 mutation.
In total, 58% (14/24) stated that appropriate genetic counseling was important:
“What if that poor man has daughters someday…a lot of things that they need to
think about and those cases I would really really hope there is a genetic
counselor helping them make the decision to implant that embryo. While a
reproductive endocrinologist is very interested in getting them pregnant with a
healthy baby, perhaps they are not equipped to really help the couple see long
term ramifications of that decision” (A).
Thirty-eight percent (9/24) responded couples may not understand a male’s cancer risk is
not zero and could still develop cancer in his lifetime:
“I think the most important thing in this situation is to make sure that they realize
that a male embryo is not without risk…that there is increased risk for certain
types of cancer…and to make sure they realize that it is not a totally risk free
option” (R)
“Just because it is a male, it does not mean that he would have no risk of any
type of cancer” (S).
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2.4.4.3 Gender selection. In total, 13% (3/24) felt this was more about gender selection
than choosing a male embryo with “less risk” of cancer and one participant (33%, 1/3)
responded that for females with a BRCA1 gene mutation, there is increased surveillance
and medical management options available:
“Breast cancer is somewhat preventable with increased surveillance and
choosing a male while it reduces his personal risk of breast cancer, you know it is
still not changing the risk for his children, his future offspring. Breast cancer is
kind of a tough one because it is very manageable. And it feels like gender
selection” (B).
Participants were asked how they felt, in general, about patients using affected
embryos when no unaffected embryos were produced. Common topics that emerged
were comfort, propriety of the use of this technology, and patient autonomy. Twenty-nine
percent (7/24) were comfortable with patients transferring affected embryos when no
unaffected embryos are produced and 100% of the seven participants agreed that it was
the patient’s choice, which they would support. In total, 75% (18/24) of participants
would support the patient’s decision to transfer an affected embryo. Thirty-three percent
(8/24) did not think this was an appropriate use of PGD technology, however, 38% (3/8)
would support the patient regardless.
Participants were asked if they had previous experience transferring affected
embryos when no disease free embryos are available after PGD. Twenty-five percent
(6/24) had encountered cases where couples transferred affected embryos after PGD,
75% (18/24) had not. When asked which conditions couples have transferred affected
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embryos for, two of these six participants stated the conditions were cancer predisposition
syndromes and one of these participants reported a case of Charcot-Marie Tooth disease.
Two participants reported cystic fibrosis cases and one reported a case for aneuploidy.
These six participants were asked if they had any concerns regarding cases where
couples transferred affected embryos after PGD. One participant (17%, 1/6) stated that
she had no concerns and the other 83% (5/6) had concerns. The main concerns that
emerged were confusion and frustration.
2.4.4.4 Confusion and frustration. Participants with concerns about patients
transferring affected embryos used key words/phrases such as “why”, “I don’t
understand”, “it’s confusing.” For 80% (4/5) that had concerns, a main concern was the
health of the child. Sixty percent (3/5) felt this was not the intended use of the
technology and two of those three participants were frustrated and confused by patients
wanting to transfer affected embryos. In total, 60% (3/5) expressed frustration/confusion:
“I wanted to say to the family, “then why did you do the test,”…It is confusing…I
think there is some frustration and then I think in my mind I am also saying to
myself this could be a sick child. You have done all of this, and you are going to
have a sick child, but then that is their decision” (A).
One participant worked with a couple that transferred a non-viable aneuploid embryo
after the physician stated the test may be inaccurate. This participant expressed her
frustration and anger in the following statement:
“The whole point of people doing this they want to improve their pregnancy rate,
they want to improve the implantation rate and they want to reduce the chance of
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loss so you are talking about aneuploidy cases so they do not want to have a
baby with a chromosome problem, they are not having a loss or a child born with
something like Down syndrome. So to me it seems a little almost disingenuous for
the physician to say well it may not be accurate let us just transfer” (I).
This same participant stated it would only take one wrongful life lawsuit before
reproductive endocrinologists would change their clinic policies:
“I am sure all it will take is just one lawsuit where someone will get pregnant and
it will be a funky mosaic…and the patient is going to say, you know what I, I
don’t understand, now I am sitting here, I am in this horrible situation, my baby,
my pregnancy is this and that and the other is probably going to say something
like that and a lawsuit before physicians, IVF physicians will think a little bit
more about whether they transfer these abnormals” (I).
In total, 100% (5/5) of the participants with concerns agreed that ultimately it was
the patient’s choice to transfer affected embryos and regardless of their own personal
beliefs, counselors would support patient autonomy.
Lastly, participants were asked how comfortable they were offering PGD to a
patient that would use affected embryos for any condition. On a scale of one to five,
where one was not comfortable at all and five was very comfortable, the majority of
participants, 71% (17/24), rated themselves as a three or less (see Figure 2.1).
2.4.5 PGD for a VUS for Marfan syndrome. Participants were presented with the
unique case scenario of using PGD for a VUS for Marfan syndrome and asked if this
scenario raised any concerns for them and, if so, what concerns. Thirteen percent (3/24)
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of participants reported no concerns and 88% (21/24) raised multiple concerns. A
significant amount of participants shared many common concerns, from which, emerged
several themes: uncertainty, directiveness of counseling provided, and lack of risk
reduction. For the “uncertainty” theme, two sub themes emerged: necessity of sufficient
evidence and is PGD necessary.
2.4.5.1 Uncertainty.
Necessity of sufficient evidence
Ninety-one percent (19/21) of participants were concerned that we cannot be
100% certain a VUS is disease causing and 68% (13/19) of these individuals strongly
encouraged family studies and felt more information/sufficient evidence was needed
regarding the pathogenicity of the variant in question in order to feel more comfortable
using PGD for a VUS. In total, 71% (15/ 21) stated sufficient evidence from family
studies was needed:
“We actually request family studies…we actually thoroughly discuss with the
couple doing PGD for this if it is not the cause you are not reducing risk” (I)
“Because of the ambiguity…I would have a very lengthy discussion about…the
fact that it is a VUS, it is not a known deleterious mutation, we could be deciding
not to transfer embryos based on…incomplete information…I would also
strongly suggest family studies…there would be a lot of counseling that would go
with it” (K).
A main concern for 10% (2/21) of participants was the exclusion of healthy embryos in
the event that the VUS was, in fact, a benign polymorphism:
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“I think the concern that you would be discarding embryos that are not actually
affected…that is probably the biggest one” (R).
Is this necessary?
Forty-three percent (9/21) questioned if PGD was necessary and 78% (7/9) said it was not
a proper use of the technology:
“I feel uncomfortable with the use of PGD for a VUS…We do not even know
whether it is the cause, does not seem like a great idea to me…” (S)
“Just a straight up variant of unknown significance, then I do not really think
that PGD has a big, large role to play in that” (P).
2.4.5.2 More directive counseling style. Eighty-one percent (17/21) responded that
PGD requests for a VUS would require more extensive counseling sessions and were
more likely to use directive counseling in this situation:
“I would have lots and lots and lots of talk about how unsure this is and this
probably the scenario that I would be most likely to be directive that it is not a
good idea to use PGD” (H).
2.4.5.3 Not reducing risk. Fifty-two percent (11/21) believed that PGD for a VUS for
Marfan did not reduce risk and a future child still could inherit Marfan syndrome and
should still be assessed for a connective tissue disorder:
“I would want to make sure that they fully understand that implanting embryos
without the VUS still has some significant risk to create a child with Marfan
syndrome” (L)
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“I think in the case of with something like Marfan syndrome we would potentially
recommend that they have a child evaluated for Marfan and know that it is
something running in the family…kind of have them watched a bit more
closely” (S).
However, 4% (8/21) of participants that had concerns stated that it was not their place to
inform a patient that they could not use PGD for a VUS:
“I am never going to be in a position where I am absolutely going to tell a
patient no I am not going to offer PGD because that is not my job…my job is to
make sure they are informed” (L).
Participants were next asked how they felt about using PGD for a VUS for
Marfan in particular. Thirteen percent (3/24) were comfortable, and 38% (9/24) were
uncomfortable:
“Genetics is such a moving target in some ways especially when it comes to
sequencing that it just makes me really uncomfortable to use something that you
do not know for sure is definitively causative or linked with the disease” (N).
From the other 11 participants, two common themes were established: proper use of the
technology and evidence-based medicine.
2.4.5.4 Proper use of the technology. Twenty-seven percent (3/11) questioned if this
was a proper use of the technology and whether or not it is a waste of resources,
including time, and money:
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“ I hate to bring anything back to money because you cannot put a price on your
child’s health and wellbeing but I feel like it would just be kind of a waste of
resources unless we have reason to believe that the VUS is disease causing” (B)
“It is kind of giving false hope to the parents” (J)
“I think it is just not enough, that is not an appropriate use of the technology,
because we are not sure that we are preventing the disease and thinking that we
are when maybe we are not can have dangerous consequences” (C).
2.4.5.5 Evidence-based medicine. The other 73% (8/11) felt that their comfort level
would depend on the information/ data (i.e. family studies, research, laboratory
classification etc.) available and counseling:
“It just depends on how much investigative work has gone on prior to
considering PGD” (D)
“It would be concerning to me that we would be doing something without really
having the science behind us, we would not really know if we are selecting for or
against anything” (W).
When asked if participants had previous experience managing cases involving
PGD for a VUS, 46% (11/24) had and 54% (13/24) had not. The 11 participants with
previous experience indicated a variety of disorders for which they have counseled for a
VUS. These conditions included muscular dystrophy (1/11), polycystic kidney disease
(1/11), Fanconi anemia (1/11), cystic fibrosis (2/11), epidermolysis bullosa (1/11),
hypertrophic cardiomyopathy (1/11), Treacher Collins syndrome (1/11), Cohen syndrome
(1/11), and 2/11 indicated counseling for multiple conditions involving a VUS.
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Participants who have counseled PGD cases for a VUS were asked what concerns
they had regarding their experiences. All 11 participants had concerns and, again,
common themes emerged. These themes were: necessity of appropriate/thorough
counseling and risks. A sub-theme of appropriate counseling was “will this truly help the
patient?”.
2.4.5.6 Necessity of appropriate/thorough counseling. All participants stressed that
patients need to be appropriately counseled for fully informed decision making and that
counseling must included a special consent process regarding the uncertainties of PGD
for a VUS:
“It would require some really, really careful consenting” (V).
Forty-six percent (5/11) stated that sufficient evidence indicating the VUS was disease
causing was needed and that family studies should be performed to help determine
pathogenicity.
Will this truly help the patient?
Fifty-five percent (6/11) felt there were numerous uncertainties and 50% (3/6) of these
individuals questioned if the technology would truly be beneficial to the patient:
“The main thing is counseling them appropriately that this may not be the cause
and that doing testing for this may, one it may not be needed and two not reduce
the risk whatsoever” (I).
2.4.5.7 Risks. Eighteen percent (2/11) of participants were concerned healthy embryos
would be discarded:
“This could rule out embryos that are in fact healthy” (T).
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Lastly, participants were asked how comfortable they were offering PGD for a
VUS for any condition. On a scale of one to five, where one was not comfortable at all
and five was very comfortable, the majority of participants 63% (15/24), rated themselves
as a two or less and four percent (1/24) were very comfortable (see Figure 2.1).
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Figure 2.1
On a scale of one to five (one being not comfortable at all, five being very comfortable)
participants’ comfort levels regarding PGD for any adult-onset condition, transferring
affected embryos when no disease free embryos are available, and PGD for a VUS.
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2.4.6 General Questions. General questions asked during interviews included ranking

the three case scenarios from least controversial to most controversial, what PGD should
and should not be used for, key factors in determining the appropriate use of PGD, what
the future holds for the use of PGD, and what concerns participants about the potential
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uses. Lastly, participants were asked if there were any other controversial uses of PGD
they would like to discuss.
Participants were first asked to rank the three case scenarios, PGD for an adultonset disorder, transferring affected embryos when no disease free embryos are produced,
and PGD for a VUS, from least controversial to most controversial. Results were
established from 23 participants as one participant felt she could not rank the scenarios in
any order. Overall, the majority (65%,15/23) of participants felt that PGD for an adultonset disorder was the least controversial, and PGD for a VUS was the most controversial
(see Figure 2.2).
Of the six participants who counsel greater than 20 PGD cases per month, and
work in a PGD laboratory or Reproductive Endocrinology clinic, 50% (3/6) stated that
transferring affected embryos was most controversial and these same participants felt that
PGD for a VUS was moderately controversial. In total, 8/23 participants stated that PGD
for a VUS was moderately controversial (6/8) or least controversial (2/8).
When asked what PGD should be used for, several themes emerged from the
discussions. Themes included: having a healthy child, what the patient perceives as
severe/burdensome, conditions that are life limiting or cause a diminished quality of life,
gender selection for X-linked conditions, and establishing clear risk of a genetic disorder.
2.4.6.1 Having a healthy child. Twenty-five percent (6/24) of participants said that
PGD should be used for “anything and everything” (L) to have a healthy child:
“I think that PGD should be used for all of these things for helping people have
the highest likelihood to have a healthy child” (E).
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Figure 2.2.
Participants’ ranking of the three case scenarios from least controversial to most
controversial.
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Chromosome abnormalities were identified as another legitimate use of PGD by 25%
(6/24):
“Most embryos have chromosome issues so the most important thing at this point
is viability, PGD really helps us pick the embryos that are most likely to result in
viability” (F).
2.4.6.2 What the patient perceives as severe/burdensome. Forty-two percent (10/24)
agreed that PGD is appropriate for couples where the disease causes significant burden to
the family:
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“PGD should be used for…a serious, life threatening conditions…I think that the
definition of severe that is a very broad term and I think it needs to be interpreted
in the context of that particular family” (D).
2.4.6.3 Conditions that are life limiting or cause a diminished quality of life. Fifty
percent (12/24) responded that PGD should be used to avoid diseases that are life limiting
or resulted in a diminished quality of life:
“I think PGD should be used to prevent suffering of a future child” (B)
“It really should be for medical purposes to avoid suffering, to avoid disease…
doesn’t necessarily have to be childhood onset, doesn’t necessarily have to be
fatal but that is sort of where the avoiding suffering comes in” (N).
2.4.6.4 Clear risk of a genetic disorder. Forty-two percent (10/24) said PGD should be
used in cases where clear risk for a genetic disorder is established. Eight percent (2/24)
felt it should be used for highly penetrant conditions:
“It should be used to test embryos for a clear risk for a significant medical
issue” (K)
“It should be used in cases where there is a clear risk for a known genetic
condition being passed on in a family” (T).
Gender for X-linked conditions
Gender selection solely for X-linked conditions was accepted by 21% (5/24) of
participants.
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Participants stated that PGD should not be used for gender selection (i.e family
balancing, or just general gender preference), conditions that are not life limiting, and
selecting for a genetic condition.
2.4.6.5 Gender selection. The majority (71%, 17/24) agreed PGD should not be used
for sex selection:
“Barebones gender is not a disease and I tend to want to do this to help avoid
disease” (I)
“I would say sex selection, but even there I have to grapple with that it is that in
my heart of hearts I believe that every baby born should be loved and so I believe
that if a couple perceives that they would love a baby more because it is a girl or
the baby is a boy, I should not stand in the way of creating that family” (G).
2.4.6.6 Conditions that are not life limiting. Fifty-four percent (13/24) thought PGD
for conditions that are not life limiting, including but not limited to positive trait
selection, was not an appropriate use of the technology:
“PGD should not be used to select for healthy traits, so I do not think it should
be used for physical features…I enjoy human variation, I think that we all have a
lot to offer” (A)
“If somebody wants to prevent polydactyly, I think that would probably be a silly
use of PGD… you know anything that is not really life limiting” (B)
“It is a good tool to prevent a significant condition from being passed on but not
necessarily something to be used to screen out a trait that a couple prefers not to
have” (S)
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“Male patterned baldness, if they wanted to use it for something insignificant
then I would be like this is such a waste of resources, it is not like impacting
quality of life” (X).
Ambiguous genetic information
For 33% (8/24), PGD for ambiguous genetic information such as a VUS, single
nucleotide polymorphisms (SNPs), and predisposition genes are other inappropriate uses
of the technology:
“SNPs that we do not know, you know like stuff on 23andMe you know the test
that have very low relative risk odd scores or low odd risks. They probably do not
have much of a place in this” (F)
“I just get uncomfortable when I start thinking about the next generation
sequencing and all the SNP chips and all that kind of stuff out there because you
and I both know and my argument here is prenatally we don’t even know what the
hell the SNPs mean so now you are going to do it on an embryo” (I).
“Aside from VUSs…I think there are a lot of genes out there and predisposition
type things that just are not ready for prime time in general…for example APOE
and the Alzheimer increased risk, I think there are things out there so
ambiguous…” (L).
2.4.6.7 Selection for a condition. Eight percent (2/24) said selecting for a genetic
condition, like deafness, was also inappropriate.

!48

For key factors in determining the appropriate use of PGD, four common themes
emerged. These themes were: diminished quality of life and life span, patient’s life
experiences, established diagnosis, and patient education.
2.4.6.8 Diminished quality of life and life span. Fifty-eight percent (14/24) responded
that diseases that result in a diminished quality of life and therefore are medically
significant were key in determining if PGD was appropriate:
“I think it should be symptom severity. If you are talking about someone not
being able to have a normal life or potentially having a chance of a shortened
lifespan then that is a reasonable thing to talk about” (A)
“Overall the impact on life or quality of life or what the disease burden is” (Q).
2.4.6.9 The life experiences of the patient. For 38% (9/24), the patient’s life
experiences influenced whether or not PGD should be used:
“It is their experience that matters, it is not my opinion that matters…For some
of them they really do feel a serious burden and a large desire to avoid passing it
on to children and so it became very easy to just make sure that every patient
knew about their options and to let them then direct me regarding how much they
wanted to know about it” (C).
2.4.6.10 There is an established diagnosis in the family. Thirty-three percent (8/24)
agreed that PGD was appropriate for an established diagnosis and known mutation:
“I think the biggest thing is to make sure that you are operating, that you are
working with things you know, that you can confirm the mutation” (W).

!
!49

2.4.6.11 Patient education. Lastly, 42% (10/24) determined that PGD was appropriate
if the patient was well educated:
“I think the most important thing is education, I think that our biggest job is to
make sure that patients understand the process, the goal of the testing and you
know possible hang ups and what the potential outcomes are and beyond that I
think that you know your biggest job is to provide education on it and it is the
patient’s job to figure out what options are going to be best for them” (H).
Participants were next asked what the future holds for the use of PGD and if they
had any concerns regarding its potential uses. Themes that were established included:
testing for things that are not medically significant, expansion of genetic testing of
embryos, accessibility, misconceptions about PGD, lack of genetic counselors in fertility
clinics, and advancements in PGD technologies. A sub-theme of testing for nonmedically significant traits was eugenics.
2.4.6.12 Expansion of genetic testing of embryos. Fifty-eight percent (14/24) believe
expansion of genetic screening of embryos, through next generation sequencing and
whole exome sequencing, is inevitable and 57% (8/14) of these participants were
concerned:
“You know what is funny about that to me?…That we will not be able to put back
any embryos” (G)
“You are not going to have any “normal” embryos” (I)
“If we start testing for “everything”, and association risk and what not, we are
not going to have any embryos to transfer because we are all at risk for
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something, we all carry things, we all, we are human beings, we are susceptible
to disease, sometimes pretty severe disease, so I, we need to keep it in check to a
certain degree (K).
2.4.6.13 Testing for traits that are not medically significant. Thirty-eight percent
(9/24) felt eventually more ambiguous, mundane, non-medically significant traits would
be commonly tested for and all nine of these participants along with seven other
participants, 67% (16/24), were worried about this occurring:
“If we start to do PGD you know for what we might term less severe conditions
or just multifactorial conditions we are going to reduce a lot of the variation in
our society and I would hate to see a society of perfect people where the few
people who are not perfect are left out” (B)
“With the use of exome sequencing it is going to be a lot more common for
people to do PGD for non-medical reasons…What could be the evolutionary long
term…what are going to be the down stream affects of …other mutations that
when we do that become more evident…are we going to find out that when we
select for those genes that there are unintended consequences…is it going to
lower the diversity in the population” (M).
Eugenics
Forty-four percent (7/16) of this group of participants are concerned this would
lead us down the path of eugenics and a “GATTACA” like future and 29% (2/7) were
worried people may someday be required to do PGD:
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“I do not want to live in GATTACA you know I do not want to live in a society
where people have to use PGD to reproduce, I do not want to live in a society
where we will not let people have kids on their own, I do not want us to have to
test every embryo and make everybody do that to have a child that that sounds
crazy but…that does scare me” (F).
However, 8% (2/24) of participants were not concerned about the potential uses, such as
positive trait selection, because genetics are extremely complicated:
“I do not have any concerns…that is how much I believe in how stupid we are.
And that is how much I believe in the complexity of life and that is how much I
believe that yes so when things happen in a lab they are incredibly artificial. And
once again, I might be naive, is that health care professionals have their own
internal checks and balances that we will never run on luck. And we will never
do things that are unethical and immoral” (G).
2.4.6.14 Accessibility. With regards to accessibility, affordability, and improved
techniques, 42% (10/24) of participants hoped or believed more people will have access
in the future:
“Unfortunately it remains unavailable due to cost for a lot of my patients, so that
is a concern that I have, I wish it were more available for those patients and I do
not know that if it is ever going to become too available because lots of patients
are not going to be ever willing to go through the process of IVF which is what is
required for PGD” (L).
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However, 17% (4/24) are worried about possible class discrimination with only the
wealthy being able to afford PGD:
“People just you know they feel that everything they want and they want it now
immediately or ten minutes ago, because it is expensive, it is very expensive and
a lot for people to go through, it is definitely its own niche [of people]” (R).
2.4.6.15 Misconceptions about PGD. Seventeen percent (4/24) were concerned about
the public’s/patient’s misconceptions:
“ I often get questions from families “well what can we test for?” Sometimes
jokingly but sometimes partially serious they ask “do we have the ability to test
for intelligence?” and things like that…I think the general public has
misconceptions about what we actually can and cannot do” (Q)
“In Hollywood right now it [genetics] is evil, it is the bad guy. Every zombie
movie is because of a genetically engineered virus and I always like to see how
science fiction kind of predicts society’s biggest fears and most of them happen to
be genetics right now and it is fun to talk to people and say you know what
honestly, that [designer babies] is not to far in the future, but no in medical
genetics that not really the focus” (U).
2.4.6.16 Lack of genetic counselors in the reproductive endocrinology field. Because
there are not enough genetic counselors in fertility clinics, 25% (6/24) were concerned
that reproductive endocrinologists will inappropriately use PGD:
“I am more concerned about the REIs, but I think most PGD labs…understand
why PGD was developed and would not be comfortable offering that to families

!53

and I would hope that REIs would not feel comfortable offering it to their
patients” (D)
“There is going to be an extremely large need for genetic counselors and very
thorough consenting and very thorough data analysis, I do not think we have the
man power for that so my fear is that things are going to fall in the hands of the
reproductive endocrinologist and things are going to be done irresponsibly” (V).
2.4.6.17 PGD is advancing. Finally, 8% (2/24) were adamant most people do not
realize how fast this field is advancing:
“People do not really know what is happening in the field, it is moving very
quickly, we tend to focus on things that are hypothetical, they are actually
happening…We like to think about “hey you know should we pick BRCA that
sounds fine”…it is not a scenario anymore, it is actually happening, we need to
be ready for it and I don’t think we are” (F).
Lastly, participants were asked if there were additional controversial aspects of
PGD. Forty-six percent (11/24) of the participants felt the study scenarios captured the
essence of controversial indication for PGD and the slippery slope that genetic counselors
find themselves traveling. The other 54% (13/24) of participants mentioned subjects
such as non-disclosure testing (8%, 1/13), BRCA positive patients being put on injectable
hormones (8%, 1/13), preimplantation genetic screening (8%, 1/13), HLA matching (8%,
1/13), the lack of guidelines (15%, 2/13), and gender selection (8%, 1/13) as other
controversies they have personally faced.
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2.5 Discussion
This study is one of the first to assess the opinions of genetic counselors regarding
controversial applications of PGD. Although practice guidelines put forth by the
American Society of Reproductive Medicine (ASRM) address specific topics of PGD,
such as adult-onset conditions, there are still gaps in the information regarding
applications that are controversial. This study looked at three such applications
including: PGD for adult onset predisposition to disease, use of embryos with genetic
disease after PGD revealed no disease-free embryos to be available, and PGD for a VUS.
Genetic counselors who have counseled PGD cases were questioned about these three
applications, and from these discussions themes were established from their opinions,
thoughts and concerns.
From the discussions we determined that certain factors influence counselors’
comfort of PGD being used for adult-onset conditions, transferring affected embryos
when no disease free embryos are available, and testing for a VUS. Themes common to
all three scenarios included: the need for appropriate/thorough counseling, the importance
of the genetic indication, patient perceptions, and respect for patient autonomy in
decision making.
2.5.1 Need for appropriate/thorough counseling. Appropriate counseling included
review of the benefits and limitations of PGD, education about the disease, and
addressing psychosocial elements. In order for patients to be fully informed, several
topics should be covered. For adult-onset disorders, many genes, including PSEN1 and
BRCA mutations, are considered predisposition genes that are not 100% penetrant.
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Mutations in predisposition genes cause increased susceptibility to developing a
particular disease but do not guarantee that symptoms will occur in the person’s lifetime
(Ormondroyd et al., 2012). For some counselors, PGD for predisposition genes or genes
that exhibit reduced penetrance is more difficult to accept as there is not a 100% risk to
the individual. Part of this concern is that we could potentially be discarding embryos
that are otherwise healthy and these potential children could have led fulfilling lives.
Therefore, for some counselors, the penetrance of the condition can affect how
comfortable they are using PGD. Another key discussion to have with patients is about
the potential of disease treatments or potential cures in the future.
While the risk of cancer developing in a BRCA positive male is significantly less
than a female’s risk, it is not negligible. Also, a BRCA positive male’s future children are
at 50% chance of inheriting the same mutation. The potential male child resulting from
the transfer of a known BRCA positive embryo may someday be put in the position of
deciding to use PGD for his own children. Although this type of scenario has the
potential for causing “uneasy” feelings in genetic counselors, most participants in this
study understood the patient’s reasoning for selecting a male embryo. Per Savulescu
(2001), if a couple knowingly chooses to transfer an embryo that is affected with a
genetic disease, then the medical professional should not express agreement or
disagreement about this decision.
Counseling for PGD should include discussion of all possible outcomes, so that
on the day of embryo transfer, couples are not forced to make immediate, emotionally
laden decisions. This includes the possibility that all embryos may be affected.
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Therefore, genetic counselors need to assist patients in considering a course of action for
each potential outcome. Patients also need to understand a potential child’s risk of
developing the disorder in question and the long term ramifications of such a decision.
Given the increased use of genetic testing through next generation sequencing
panels, microarray, and whole exome/genome studies, requests to use PGD to test for a
VUS is likely to increase. As a VUS has not been defined as clinically significant or
predictive of an individual’s phenotype, the appropriateness of PGD for a VUS is
debatable. The presented scenario of PGD for a VUS for Marfan syndrome raised
multiple concerns for the majority of participants in this study, and participants expressed
concern about PGD for a VUS for any genetic condition. Because a VUS is not
definitively disease causing, transferring embryos that lack the VUS does not guarantee
that the potential child will not have the disease (Reiff et al., 2012). In addition,
discarded embryos that carry the VUS could be disease free. Most participants expressed
that sufficient evidence is needed to support that the VUS was disease causing including
research, laboratory classification, and family studies to determine if the VUS tracks with
affected family members.
According to the principle of non-directive counseling, medical personnel should
provide patients with information about risks and options to reduce these risks
(Savulescu, 2001). Although non-directive counseling is a central tenet of the genetic
counseling profession, a more directive counseling style may need to be considered in
both the situations of PGD for a VUS and when considering transferring affected
embryos when no disease free embryos are available. Patients need to be extensively
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counseled that selecting against a VUS may not be reducing the risk of passing on the
condition in question, and children born after PGD should still be evaluated by a
geneticist for the disease. On a more practical note, unless there is evidence in support of
the pathogenicity of the variant, some believe PGD for a VUS is not an appropriate use of
the technology and may be a misuse of patient’s time and money, as well as medical
resources. However, some people believe that PGD should be used to reduce uncertainty,
and therefore PGD for a VUS would be appropriate since that would accomplish this
goal.
2.5.2 Patient Perceptions. Counselors felt it was important to discuss how
burdensome a disease has been in the patient’s life. Many factors are considered in
determining which conditions are labeled as “serious” including penetrance, potential for
treatment, progression, age of onset, and severity of symptoms (Krahn, 2009). However,
it is important to remember that every patient’s perception of what is “serious” or
“burdensome” is different (Miller & Levine, 2013). Genetic counselors should
specifically address the unaffected spouse and discuss how he/she feels about caring for a
new baby and the spouse, both with a genetic condition, some that are potentially life
threatening.
2.5.3 Patient Autonomy. For many counselors, regardless of their own personal
feelings, patient autonomy was of utmost importance. Ultimately, patient’s choices will
affect their own lives, and it is not the position of a provider to say whether they can or
cannot use PGD. Genetic counselors have a responsibility however, to ensure patients
are appropriately counseled and fully informed about the benefits and limitations of PGD.
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Most genetic counselors believe patients have procreative autonomy. The basis of
procreative autonomy is that couples are free to decide what kind of children to have, as
well as when and how to have these children (Savulescu, 2001).
2.5.4 General Questions
2.5.4.1 Least controversial and most controversial scenarios. Overall, the majority of
participants stated PGD for a VUS was the most controversial scenario of the three
scenarios presented, while PGD for adult-onset conditions was the least controversial.
This finding was most likely due to the uncertainty of a VUS being disease causing.
Having an established diagnosis with a known disease causing mutation made
participants more comfortable offering PGD.
Testing for an adult-onset condition, with an identifiable mutation, was easier for
participants to accept, possibly because it is no longer considered a “novel” idea and has
been done more frequently. With expansion in genetic testing, more “novel” ideas, like
PGD for a VUS, and PGD for ambiguous genetic information will create unease among
professionals. In the beginning, new concepts are prone to be controversial and cause
discomfort.
A counselor’s experience with PGD may have influenced their opinions. Six
genetic counselors reported having counseled 20 or more PGD cases per month. Four of
these genetic counselors work in a PGD laboratory setting and the other two work in
Reproductive Endocrinology clinics. We determined that the majority of this subset of
participants that felt transferring affected embryos was most controversial, worked in a
PGD laboratory or Reproductive Endocrinology clinic. A potential explanation could be
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that genetic counselors in these two settings feel that the intended use of the technology is
to transfer unaffected embryos. Of the participants that stated PGD for a VUS was
moderately or least controversial, half of them worked in these two settings. This could
be because they have more experience addressing VUS cases and the issues are less
novel.
2.5.4.2 Counselors opinions regarding what PGD should and should not be used.
Participants stated that PGD should be used for the purpose of having healthy children.
The ultimate goal of PGD is to produce healthy children and avoid suffering. In order for
this to be possible, participants felt that there needs to be a clearly established risk of an
inherited genetic disorder within a family.
Half of the participants also felt PGD was appropriate for conditions that are life
limiting or cause reduced quality of life. It is important to consider a patient’s perception
of which conditions are serious or burdensome enough to warrant the use of PGD. Most
providers cannot fully understand or appreciate the experiences of individuals whose
families are stricken with genetic conditions. For some, having a child with a BRCA
mutation may be acceptable because there is treatment, increased surveillance and
medical management options. For another whose family has been devastated by the
disease, they may decide that the disease needs to “end with them” and not be transmitted
to future generations.
When considering what PGD should not be used for, participants stated that
gender selection, testing for ambiguous genetic information, HLA matching and selecting
for (rather than against) a genetic condition were inappropriate. With regard to gender
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selection, the majority felt PGD should not be used as gender is not a “disease.”
However, the caveat here is that for X-linked conditions, gender selection is the easiest
method of selecting out embryos and therefore was considered the only appropriate
reason for gender selection.
The majority of counselors raised concerns about testing for conditions that are
not necessarily life limiting or testing for ambiguous genetic information. For example,
positive trait selection is not life limiting. Over half of the participants felt that PGD
should not be used to select for “healthy traits” such as hair color, eye color, height, or
athleticism. A common reason for this belief was that human variation was appealing to
participants. Participants expressed that PGD should be used to prevent significant health
problems, but should not necessarily be used to select for traits that a couple prefers to
have. Another consideration is that testing for traits that do not impact quality of life is a
waste of resources.
Participants indicated that ambiguous genetic information included: VUSs, single
nucleotide polymorphisms (SNPs), and predisposition genes. With the development of
tests such as that provided by the company 23andMe, in which the genetic information
present often has low relative risk scores, people may request PGD for SNPs and
predisposition genes. The problem is that with VUSs, SNPs and predisposition genes
there is not enough evidence to support using these indications for PGD.
2.5.4.3 Key factors in determining the appropriate use of PGD. There were five
common themes that were key in determining appropriate uses of PGD. The majority of
participants felt that PGD was an appropriate use if conditions were life limiting and
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resulted in a diminished quality of life. Participants were more comfortable when
symptom severity and disease burden were significant. The patient’s life experiences
were a common theme throughout the study and was key in determining the
appropriateness of PGD. Ultimately, a patient’s experiences superseded counselor
opinions. Also, participants were more at ease with offering PGD if there was an
established diagnosis with a known pathogenic mutation. Last, participants believed
patient education was important in determining if PGD was appropriate. Genetic
counselors must ensure that the patient is well educated about the PGD process, the
benefits and disadvantages, and the potential outcomes of PGD, and ultimately, patients
must decide on the course of action that is most appropriate for their families.
2.5.4.4 The future of PGD and counselors concerns about its potential uses. Overall,
the majority of counselors interviewed had concerns about the potential uses of PGD.
Participants responded that PGD is likely to eventually be used to test for non-medically
significant traits, that there would be expanded testing of embryos, and that accessibility
would change. Participants had concerns about these eventual uses but were also
concerned about patient/public misconceptions, and the lack of genetic counselors in
fertility clinics. However, two participants were not concerned about future uses, such as
positive trait selection, because of the complexity of genetics, and how difficult it would
be genetically manipulate or engineer individuals.
The majority of genetic counselors interviewed believed that next generation
sequencing and whole genome/exome sequencing will be used to screen embryos and
half of these participants were concerned about this testing. The concern was that no
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“normal” embryos will be available for transfer because every embryo is susceptible to
disease. If these extensive tests are used on embryos, the pool of embryos would most
likely be eliminated. Additionally, one must consider who will be responsible for
deciding which embryo to transfer after WGS or NGS, will it be the parent or the
physician?
Participants also felt that eventually PGD is likely to be used to test for more
ambiguous, mundane, non-medically significant traits. The majority were concerned
about this potential use of PGD. A concern was that there will be unintended
consequences when selecting for certain traits, such as reducing genetic variation within
the population. Another concern is that this will lead us down the path of eugenics
towards a “GATTACA” future. GATTACA is the title of a science fiction movie where
society is driven by eugenics and children are artificially created to have the most
advantageous traits. Some participants expressed worry that people may someday be
required to do PGD, as depicted in this film.
Many participants hoped that PGD will become more accessible, affordable, and
technically improved. Unfortunately PGD is currently unavailable to many patients
because of its high cost. However, even if PGD does become affordable, many “patients
are not going to be ever willing to go through the process of IVF” (F), because of all that
it entails. Some participants were concerned about possible class discrimination, where
only the wealthy are able to afford PGD.
Another concern for participants was the public’s/patient’s misconceptions about
PGD. In many movies today, genetics is a central theme and this and other popular

!63

media may create misconceptions. People often assume that it is possible to test for
every disease, pick and choose physical characteristics, or engineer “designer babies.”
Efforts to disperse these misconceptions are needed in order for patients and the medical
community to understand this is not the primary focus in medical genetics.
A main issue that emerged from participants is that there are not enough genetic
counselors involved in the fertility field. Most fertility clinics do not work in association
with genetic counselors and several participants in this study expressed worry that
reproductive endocrinologists will inappropriately or irresponsibly offer PGD. Genetic
counselors could be extremely valuable in these environments, offering guidance for
screening and testing of both the couples and their embryos.
2.5.5 Study Limitations. The group of participants was limited to genetic counselor
members of the NSGC that have experience counseling PGD cases. The majority of
participants were young and inexperienced, which may have affected results. More
experienced PGD counselors may be more comfortable with controversial scenarios.
Biases may have been created as each scenario is just one example and perhaps
participants would have had different responses to different scenarios. Additionally, there
is likely a response bias since genetic counselors who do not counsel for PGD might be
less likely to offer their participation. It should also be considered that some participants
are guided by laboratory policy, and may not have expressed their own opinions and
instead expressed the laboratory’s opinions. Also, only the opinions and attitudes of
genetic counselors were reported in this study. It does not examine the thoughts and
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perceptions of the reproductive endocrinologists or other individuals involved in caring
for patients who are contemplating PGD, where different perspectives may be present.
2.5.6 Practice Implications. Our findings shed light on genetic counselors’
perceptions about current and future uses of PGD. We have identified key areas where
tension between advances in PGD and genetic counselors experience significant ethical
dilemmas or controversy. Awareness of these key areas will aid genetic counselors in the
practice setting and also provide areas for needed research in the future. It will also
ensure that genetic counselors who are not currently involved with PGD are cognizant of
recent advances in the potential role for genetic counselors in the fertility setting.
2.6 Conclusion
With advancements in genetic diagnostic technology, PGD has expanded to
incorporate indications that may be considered controversial. For controversial
applications of PGD, five common themes emerged with regards to determining if PGD
was appropriate. Participants stated PGD is appropriate for conditions that are life
limiting and cause a diminished quality of life. When symptom severity and disease
burden were significant, participants were more comfortable. Having an established
diagnosis with a known pathogenic mutation, also contributed to counselors’ comfort.
Patient’s life experiences were also key in determining if PGD was appropriate.
Participants felt that thorough counseling and education of patients was crucial; however,
patient autonomy superseded counselors’ concerns. Even though PGD for certain
conditions causes discomfort for some counselors, the value of the technology was
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recognized by all participants and ultimately, patients need to decide on a course of action
that is most appropriate for their families.
As more novel uses of PGD are performed, counselors will need to quickly adapt.
Common indications for PGD, like PGD for adult-onset disorders, was initially
controversial, however, as more individuals have sought PGD for this reason, genetic
counselors have become more at ease with PGD for this use. It is possible that eventually
genetic counselors may reach the same level of comfort with using PGD for a VUS and
other controversial applications. It is our hope that this study will bring attention to this
growing field, and promote education among genetic counselors.
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Chapter 3. Conclusion
With advancements in genetic diagnostic technology, PGD has expanded to
incorporate indications that may be considered controversial. For controversial
applications of PGD, five common themes emerged with regards to determining if PGD
was appropriate. Participants stated PGD is appropriate for conditions that are life
limiting and cause a diminished quality of life. When symptom severity and disease
burden were significant, participants were more comfortable. Having an established
diagnosis with a known pathogenic mutation, also contributed to counselors’ comfort.
Patient’s life experiences were also key in determining if PGD was appropriate.
Participants felt that thorough counseling and education of patients was crucial; however,
patient autonomy superseded counselors’ concerns. Even though PGD for certain
conditions causes discomfort for some counselors, the value of the technology was
recognized by all participants and ultimately, patients need to decide on a course of action
that is most appropriate for their families.
As more novel uses of PGD are performed, counselors will need to quickly adapt.
Common indications for PGD, like PGD for adult-onset disorders, was initially
controversial, however, as more individuals have sought PGD for this reason, genetic
counselors have become more at ease with PGD for this use. It is possible that eventually
genetic counselors may reach the same level of comfort with using PGD for a VUS and
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other controversial applications. It is our hope that this study will bring attention to this
growing field, and promote education among genetic counselors.
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Appendix A: Invitation letter to Participants

Invitation to Participate: Genetic Counselors Opinions and Attitudes Towards Uses of
PGD

!

Dear Genetic Counselor,
You are invited to participate in a master of science thesis research study at the
University of South Carolina School of Medicine. The objective of this study is to
explore the opinions and attitudes of genetic counselors when dealing with controversial
uses of preimplantation genetic diagnosis.
Participation in this study is intended to benefit the genetic counseling field by
revealing how genetic counselors view various issues. We believe that the study results
will demonstrate the opinions and attitudes of counselors regarding use of PGD as no
previous studies have focused on this topic. We feel that this study will add information
to the discussion concerning applications of PGD technology.
If you decide to participate, you will be asked to complete a qualitative survey
over the telephone asking a series of questions about various issues that you may
encounter in practice. Your verbal consent will be obtained before the survey begins.
The interview should take approximately 30 minutes. You do not have to answer any
questions that you do not wish to answer and you can stop taking the survey at any time.
The interview will be recorded to ensure accuracy; all identifying information will be
deleted after the interview.
If you have any questions, or would like more information, please contact the
principal investigator (or my faculty advisor, Janice Edwards), using the contact
information below. If you have any questions about your rights as a research participant,
you may contact the Office of Research Compliance at the University of South Carolina
at 803-777-7095. Thank you for considering participating in this research project. Your
input is invaluable, and we appreciate your time!
Kristen Everton
Genetic Counseling Intern
University of South Carolina School of
Medicine
Genetic Counseling Program
2 Medical Park, Suite 103
Columbia, SC 29203
phone: (954) 292-0690
Kristen.Everton@uscmed.sc.edu

Janice G. Edwards, MS, CGC
Clinical Professor and Director,
University of South Carolina School of
Medicine
Genetic Counseling Program
2 Medical Park, Suite 103
Columbia, SC 29203
(803) 545-5706
janice.Edwards@uscmed.sc.edu
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Appendix B: Verbal Consent

You are invited to participate in a master of science thesis research study at the University
of South Carolina because of your experience with preimplantation genetic diagnosis
(PGD) cases. The purpose of the survey is to explore the opinions and attitudes of
genetic counselors when dealing with controversial uses of PGD. This telephone
interview will be recorded and all identifying information will be deleted after the
interview. Your participation is voluntary and you may skip any questions that you do
not feel comfortable answering. You may stop participating at any time. This survey
should take approximately thirty minutes. If you have any questions about your rights as
a research participant, you may contact the Office of Research Compliance at the
University of South Carolina at 803-777-7095. Do you consent to participate in this
study?

!
Yes/No
!
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!
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Appendix C: Survey

I.

Introduction/Directions
You are invited to participate in a thesis research study at the University of South
Carolina School of Medicine. The objective of this study is to explore the opinions and
attitudes of genetic counselors when dealing with controversial uses of preimplantation
genetic diagnosis. You will be presented with three case scenarios regarding
controversial uses of PGD. For each scenario, you will be asked several open ended
questions. At the end, several general questions regarding the use of PGD will also be
asked. The survey should take approximately 30 minutes to complete.
II. Demographic Questions
A. Gender/ Age:
B. Number of years in practice as a genetic counselor:
C. Number of months/years you have counseled for PGD:
D. Number of all PGD cases seen per month:
E. Location of practice: State
F. Setting of practice: PGD Laboratory Setting, Reproductive Endocrinology
Setting, Other
III. Case Scenarios
A. PGD for an Adult-Onset Condition: A woman and her husband request PGD for
early onset Alzheimer. A disease causing mutation in the PSEN1 gene has been
identified. PSEN1 mutations account for 70% of early onset Alzheimer cases.
These cases are diagnosed before the age of 65.
1. Does this scenario for early onset Alzheimer raise any concerns for you and if
so, what concerns are raised?
2. How do you feel about using PGD to identify embryos at risk for early onset
Alzheimer?
3. Have you had any cases that included using PGD for an adult-onset condition?
a) Describe the case
b) What was the condition?
c) Did you have any concerns?
4. On a scale of 1 to 5 (1 being not comfortable at all, 5 being very comfortable),
how comfortable are you offering
a) PGD for any adult-onset condition?
B. PGD to Select for a Genetic Condition: A couple requests PGD because of a
family history of breast cancer. The mother carries a disease causing mutation in
the BRCA1 gene. All of the female embryos and the only male embryo are found
to carry the mutation as well. The couple decides to implant the only male
embryo.
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1. Does this scenario raise any concerns for you and if so, what concerns are
raised?How do you feel about your patients using affected embryos when no
unaffected embryos are produced?
2. Have you had any cases that you have managed personally that included
transferring affected embryos after PGD?
a) Describe the case
b) What was the condition?
c) Did you have any concerns?
3. On a scale of 1 to 5 (1 being not comfortable at all, 5 being very
comfortable), how comfortable are you offering PGD to a patient that will
a) Use affected embryos for any condition
C. PGD for a Variant of Unknown Significance (VUS): A couple requests PGD
because the husband has Marfan syndrome. However, no known mutation was
identified. Instead, a VUS was found. The couple wants to use PGD to select
against the VUS, since there is the possibility that it may be the cause of the
husband’s Marfan syndrome. Individuals with Marfan can be mildly to severely
affected, those that are mildly affected can go undiagnosed for their entire life and
have no major health concerns.
1. Does this scenario raise any concerns for you and if so, what concerns are
raised?
2. How do you feel about using PGD for a VUS for Marfan?
3. Have you had any cases that you have managed personally that included using
PGD for a VUS?
a) Describe the case
b) What was the condition?
c) Did you have any concerns?
4. On a scale of 1 to 5 (1 being not comfortable at all, 5 being very comfortable),
how comfortable are you offering PGD for
a) A VUS for any condition?
D. General Questions:
1. Rank the three case scenarios, according to how you personally feel, from
least controversial to most controversial.
2. What do you feel PGD should be used for?
3. Is there anything you feel PGD should not be used for?
4. What are some key factors in determining the appropriate use of PGD?
5. What do you believe the future will hold for the use of PGD?
6. What concerns you about its potential uses?
7. Is there anything else you would like me to know about the controversial uses
of PGD?
IV. Thank you.
Thank you for your participation in this thesis research study, it has been greatly
appreciated. Your input is invaluable. It is my hope that this research will provide
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valuable perspectives from genetic counselors who work with PGD to the discussion
concerning controversial applications of the technology.
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